However, despite these limitations, a careful analysis of the available data can suggest a rational approach to vaccinating children with cancer in order to assure adequate protection against vaccine-preventable diseases without significantly increasing the occurrence of adverse events.

The main aim of this review is to analyse data regarding the immunogenicity, efficacy, safety and tolerability of the vaccines usually recommended in the first years of life in order to help pediatricians choose the best Selleck AT13387 immunisation programme for children with cancer receiving standard-dose chemotherapy. Most children with cancer still seem to have a perfectly functioning immune system at the time of disease presentation. The concentrations of total immunoglobulins and antibodies against specific vaccine antigens are usually in the normal range [8], [9], [10] and [11]. Peripheral blood T cell levels seem

to be reduced in only a marginal number of cases: significant lymphopenia has been Pomalidomide in vivo found in only a small number of patients with leukemia [12] and in a few subjects with previously untreated Hodgkin’s lymphoma [13], Burkitt’s lymphoma [14] or sarcoma [15]. This means that the protection offered by vaccines administered before the onset of cancer is maintained by humoral and cellular immunity in most children. Moreover, if a vaccine is administered between the onset of cancer and its diagnosis, a poor immune response and severe adverse reactions seem to be unlikely [12] and [15] except in the case of conditions such as Hodgkin’s or Burkitt’s disease in which the number and function

of T lymphocytes may be significantly impaired [13] and [14]. However, after the start of chemotherapy, the immune system is rapidly and significantly compromised. Most of the drugs used to treat malignancies have a negative effect on humoral and cellular immunity, and the damage to the immune system is related to both the dose and the duration of administration [1], [16] and [17]. Cyclophosphamide, TCL 6-mercaptopurine, fludarabine and steroids seem to induce the greatest damage [1]. The most important aspect of cytotoxic antineoplastic therapy-induced immunosuppression is lymphocyte depletion. This only marginally affects NK cells but has a profound impact on circulating CD3+ and CD4+ T cells [16], whose number dwindles immediately after the start of cancer therapy and remains significantly lower than normal throughout its continuation [1]. Furthermore, T cells may undergo major functional alterations, such as a heightened susceptibility to activation-induced programmed cell death [17], or their activity may be inhibited by the suppressor factors produced by the expanded monocyte population [1]. B cells are also subject to profound depletion and, although serum IgG levels are not always significantly reduced, serum IgM and IgA levels are considerably decreased [1].